The TGF-beta2 specific antisense oligonucleotide AP 12009 as immunotherapy in high-grade glioma: A clinical phase IIB study

Hau, P. and Grisold, W. and Mahapatra, M. and Mehdorn, M. and Parfenov, V. E. and Pichler, J. and Zaaroor, M. and Bogdahn, U. and Schlingensiepen, K. H. (2005) The TGF-beta2 specific antisense oligonucleotide AP 12009 as immunotherapy in high-grade glioma: A clinical phase IIB study. In: 2nd Quadrennial Meeting of the World Federation of Neuro-Oncology/Sixth Meeting of the European Association for Neuro-Oncology, May 05-08, 2005, Edinburgh, Scotland.

Full text not available from this repository.
Item Type: Conference or Workshop Item (UNSPECIFIED)
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Neurologie
Depositing User: Petra Gürster
Date Deposited: 14 Apr 2022 06:58
Last Modified: 14 Apr 2022 06:58
URI: https://pred.uni-regensburg.de/id/eprint/35961

Actions (login required)

View Item View Item